{"transactions":[{"id":676705,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-25T20:25:06.000Z","date":"2026-08-24","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 1/4 of the underlying shares on August 24, 2027, and vests as to 1/48 of the underlying shares monthly thereafter."}],"balance_after":20000,"derivative":{"exercise_price":102.42,"expiration_date":"2036-08-23","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000907654-26-000084","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000084/form4.xml","form_type":"4"}},{"id":676704,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-08-25T20:25:06.000Z","date":"2026-08-24","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The grant vests as to 1/4 of the shares on September 14, 2027, with the balance vesting in 12 equal quarterly installments thereafter."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0000907654-26-000084","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000090765426000084/form4.xml","form_type":"4"}},{"id":864744,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-04T01:43:03.000Z","date":"2026-02-27","kind":"grant","planned":true,"acquired":true,"shares":77000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":77000,"derivative":{"exercise_price":26.97,"expiration_date":"2036-02-27","underlying":"Common Stock","underlying_shares":77000},"source":{"system":"sec-edgar","filing":"0001628280-26-014328","document":"wk-form4_1772588580.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000162828026014328/wk-form4_1772588580.xml","form_type":"4"}},{"id":864743,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-04T01:43:03.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":103,"price":25.9149,"value":2669.2347,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.70 to $26.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":175178,"source":{"system":"sec-edgar","filing":"0001628280-26-014328","document":"wk-form4_1772588580.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000162828026014328/wk-form4_1772588580.xml","form_type":"4"}},{"id":864742,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-04T01:43:03.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":3584,"price":25.161,"value":90177.024,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.69 to $25.67, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":175281,"source":{"system":"sec-edgar","filing":"0001628280-26-014328","document":"wk-form4_1772588580.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000162828026014328/wk-form4_1772588580.xml","form_type":"4"}},{"id":864741,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-04T01:43:03.000Z","date":"2026-02-27","kind":"grant","planned":true,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Constitute Restricted Stock Units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the \"Vesting Commencement Date\"), of each year beginning March 1, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":178865,"source":{"system":"sec-edgar","filing":"0001628280-26-014328","document":"wk-form4_1772588580.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000162828026014328/wk-form4_1772588580.xml","form_type":"4"}},{"id":918861,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-05T00:21:08.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":2052,"price":25.4984,"value":52322.7168,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligation in connection with the vesting of Restricted Stock Units (\"RSUs\"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the \"Vesting Commencement Date\"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.745 to $25.68, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 724 shares purchased under the Issuer's Employee Stock Purchase Plan on November 30, 2025."}],"balance_after":148865,"source":{"system":"sec-edgar","filing":"0001628280-26-005566","document":"wk-form4_1770250865.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000162828026005566/wk-form4_1770250865.xml","form_type":"4"}},{"id":1003388,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-10T22:42:16.000Z","date":"2025-11-06","kind":"sale","planned":false,"acquired":false,"shares":29131,"price":25.1597,"value":732927.2207,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.2600, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":150193,"source":{"system":"sec-edgar","filing":"0001994805-25-000008","document":"wk-form4_1762814533.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000199480525000008/wk-form4_1762814533.xml","form_type":"4"}},{"id":1022792,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-10-06T19:15:24.000Z","date":"2025-10-02","kind":"sale","planned":true,"acquired":false,"shares":297,"price":20.7801,"value":6171.6897,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units granted on February 22, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $20.5593 to $20.995, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 724 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2025."}],"balance_after":179324,"source":{"system":"sec-edgar","filing":"0001994805-25-000005","document":"wk-form4_1759778121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000199480525000005/wk-form4_1759778121.xml","form_type":"4"}},{"id":1022791,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-10-06T19:15:24.000Z","date":"2025-10-02","kind":"sale","planned":true,"acquired":false,"shares":4207,"price":19.9885,"value":84091.6195,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units granted on February 22, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $19.545 to $20.502, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":178897,"source":{"system":"sec-edgar","filing":"0001994805-25-000005","document":"wk-form4_1759778121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000199480525000005/wk-form4_1759778121.xml","form_type":"4"}},{"id":1139951,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-05-20T20:37:02.000Z","date":"2025-05-19","kind":"sale","planned":true,"acquired":false,"shares":7451,"price":14.0719,"value":104849.7269,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (\"RSUs\") granted on February 22, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $13.6763  to $14.49, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":183104,"source":{"system":"sec-edgar","filing":"0002065881-25-000009","document":"wk-form4_1747773410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000206588125000009/wk-form4_1747773410.xml","form_type":"4"}},{"id":1225830,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-05T00:43:19.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":43000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":43000,"derivative":{"exercise_price":13.69,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":43000},"source":{"system":"sec-edgar","filing":"0001787306-25-000039","document":"wk-form4_1741135393.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000039/wk-form4_1741135393.xml","form_type":"4"}},{"id":1225829,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-05T00:43:19.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":99000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":99000,"derivative":{"exercise_price":13.69,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":99000},"source":{"system":"sec-edgar","filing":"0001787306-25-000039","document":"wk-form4_1741135393.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000039/wk-form4_1741135393.xml","form_type":"4"}},{"id":1225828,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-03-05T00:43:19.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the \"Vesting Commencement Date\"), of each year beginning March 1, 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":190555,"source":{"system":"sec-edgar","filing":"0001787306-25-000039","document":"wk-form4_1741135393.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000039/wk-form4_1741135393.xml","form_type":"4"}},{"id":1225827,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-03-05T00:43:19.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the \"Vesting Commencement Date\"), of each year beginning March 1, 2026, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":173555,"source":{"system":"sec-edgar","filing":"0001787306-25-000039","document":"wk-form4_1741135393.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000039/wk-form4_1741135393.xml","form_type":"4"}},{"id":1283441,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-05T01:00:40.000Z","date":"2025-02-03","kind":"sale","planned":true,"acquired":false,"shares":2173,"price":12.7,"value":27597.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (\"RSUs\"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the \"Vesting Commencement Date\"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.545 to $13.0096, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective\nprice within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the adjusted total which includes the acquisition of 1,093 shares under the Company's Employee Stock Purchase Plan on November 30, 2024, respectively, which transactions were exempt from Section 16(a) and (b) and were erroneously reported as non-exempt purchases in the Reporting Person's Form 4 filed on December 3, 2024."}],"balance_after":135555,"source":{"system":"sec-edgar","filing":"0001787306-25-000013","document":"wk-form4_1738717233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000013/wk-form4_1738717233.xml","form_type":"4"}},{"id":1344266,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-12-03T21:17:09.000Z","date":"2024-11-30","kind":"purchase","planned":false,"acquired":true,"shares":1093,"price":7.106,"value":7766.858,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the purchase transaction of the Company's Employee Stock Purchase Plan."}],"balance_after":137728,"source":{"system":"sec-edgar","filing":"0001787306-24-000169","document":"wk-form4_1733260622.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000169/wk-form4_1733260622.xml","form_type":"4"}},{"id":1391332,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-10-03T20:55:34.000Z","date":"2024-10-02","kind":"sale","planned":true,"acquired":false,"shares":3725,"price":10.0122,"value":37295.445,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was made pursuant to the Issuer's mandatory sell-to-cover requirements implemented to satisfy the tax withholding obligations associated with the vesting of the Reporting Person's Restricted Stock Units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $9.51 to $10.31, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":136635,"source":{"system":"sec-edgar","filing":"0001787306-24-000136","document":"wk-form4_1727988928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000136/wk-form4_1727988928.xml","form_type":"4"}},{"id":1508376,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-05-20T21:12:38.000Z","date":"2024-05-17","kind":"sale","planned":false,"acquired":false,"shares":7640,"price":8.9767,"value":68581.988,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the RSUs, the shares were sold upon the vesting of the RSUs solely to cover applicable tax withholding."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $8.76 to $9.115, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":140360,"source":{"system":"sec-edgar","filing":"0001787306-24-000081","document":"wk-form4_1716239548.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000081/wk-form4_1716239548.xml","form_type":"4"}},{"id":1508375,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-05-20T21:12:38.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\"), initially granted on February 22, 2024, in which the shares were subject to a performance-based vesting condition, which was deemed satisfied on May 16, 2024 (the \"Vesting Commencement Date\").  Therefore, 50% of the shares vested on May 16, 2024 and the remaining 50% of the shares vest on May 16, 2025, subject to the Reporting Person's continued service with the Company through the applicable vesting date."}],"balance_after":148000,"source":{"system":"sec-edgar","filing":"0001787306-24-000081","document":"wk-form4_1716239548.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000081/wk-form4_1716239548.xml","form_type":"4"}},{"id":1677462,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-17T21:34:23.000Z","date":"2024-01-12","kind":"grant","planned":false,"acquired":true,"shares":176000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the  \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":176000,"derivative":{"exercise_price":3.64,"expiration_date":"2034-01-12","underlying":"Common Stock","underlying_shares":176000},"source":{"system":"sec-edgar","filing":"0001787306-24-000010","document":"wk-form4_1705527248.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000010/wk-form4_1705527248.xml","form_type":"4"}},{"id":1677461,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-01-17T21:34:23.000Z","date":"2024-01-12","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute Restricted Stock Units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on February 1, (the \"Vesting Commencement Date\"), of each year, beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":88000,"source":{"system":"sec-edgar","filing":"0001787306-24-000010","document":"wk-form4_1705527248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000010/wk-form4_1705527248.xml","form_type":"4"}},{"id":1766443,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-10-04T01:45:12.000Z","date":"2023-09-27","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest and become exercisable as to 25% of the shares subject to the option on October 1, 2024, and the remaining options will vest at 2.0833% subject to the options on each monthly anniversary thereafter, subject to Reporting Person's continued service through the applicable vesting date."}],"balance_after":240000,"derivative":{"exercise_price":5.58,"expiration_date":"2033-09-27","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001787306-23-000113","document":"wk-form4_1696383903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000113/wk-form4_1696383903.xml","form_type":"4"}},{"id":1766442,"issuer":{"id":4236,"kind":"organization","name":"Arcutis Biotherapeutics, Inc.","symbol":"ARQT"},"owners":[{"id":20104,"kind":"person","name":"Edwards Larry Todd","position":1,"cik":"0001994805","reported_name":"Edwards Larry Todd","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-10-04T01:45:12.000Z","date":"2023-09-27","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Restricted Stock Units (\"RSUs\") will vest as to 25% of the RSUs  on each annual anniversary of October 1, 2023, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001787306-23-000113","document":"wk-form4_1696383903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000113/wk-form4_1696383903.xml","form_type":"4"}}]}